Fulgent Genetics (NASDAQ:FLGT) Stock Rating Lowered by Wall Street Zen

Fulgent Genetics (NASDAQ:FLGT) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

FLGT has been the subject of a number of other research reports. Raymond James Financial reiterated an “outperform” rating and issued a $36.00 target price on shares of Fulgent Genetics in a research report on Friday, November 14th. Zacks Research cut shares of Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, February 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulgent Genetics in a research note on Thursday, January 22nd. Finally, Piper Sandler increased their price objective on Fulgent Genetics from $21.00 to $30.00 and gave the stock a “neutral” rating in a report on Tuesday, November 11th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $32.00.

Fulgent Genetics Trading Up 2.7%

Shares of NASDAQ FLGT opened at $14.63 on Friday. Fulgent Genetics has a one year low of $13.46 and a one year high of $31.04. The business has a 50-day moving average price of $24.37 and a two-hundred day moving average price of $24.62. The firm has a market capitalization of $456.89 million, a PE ratio of -7.46 and a beta of 0.94.

Fulgent Genetics (NASDAQ:FLGT) last issued its earnings results on Friday, February 27th. The company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.14. The company had revenue of $83.34 million for the quarter, compared to the consensus estimate of $85.38 million. Fulgent Genetics had a negative return on equity of 2.22% and a negative net margin of 18.75%.Fulgent Genetics has set its FY 2026 guidance at -1.450–1.450 EPS. Research analysts anticipate that Fulgent Genetics will post -0.85 EPS for the current year.

Institutional Investors Weigh In On Fulgent Genetics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd lifted its position in shares of Fulgent Genetics by 214.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,834 shares of the company’s stock worth $48,000 after purchasing an additional 1,251 shares during the last quarter. XTX Topco Ltd grew its holdings in Fulgent Genetics by 33.1% in the 4th quarter. XTX Topco Ltd now owns 22,195 shares of the company’s stock valued at $583,000 after buying an additional 5,523 shares during the last quarter. Susquehanna Portfolio Strategies LLC increased its position in Fulgent Genetics by 13.4% in the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 38,480 shares of the company’s stock worth $1,011,000 after buying an additional 4,560 shares during the period. RTW Investments LP bought a new position in Fulgent Genetics in the 4th quarter worth approximately $18,521,000. Finally, Oxford Asset Management LLP acquired a new position in shares of Fulgent Genetics during the fourth quarter worth approximately $254,000. 48.06% of the stock is owned by institutional investors and hedge funds.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.